Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 548

Sort by

Sort Order Select

Journal Articles

CLL cells are moved by the MARCKS brothers

Jan A. Burger

Blood (2021) 138 (7): 503–504.

https://doi.org/10.1182/blood.2021011650

Published: 2021

Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch

Blood (2021) 138 (2): 106–107.

https://doi.org/10.1182/blood.2021011937

Published: 2021

Journal Articles

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt

Blood (2021) 138 (2): 149–159.

https://doi.org/10.1182/blood.2020009813

Published: 2021

Includes: Supplemental data

Journal Articles

Familial patterns of hematologic precursors

Ola Landgren, Francesco Maura

Blood (2021) 137 (15): 1992–1993.

https://doi.org/10.1182/blood.2020010035

Published: 2021

Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood (2021) 137 (15): 2046–2056.

https://doi.org/10.1182/blood.2020006322

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Single Cell Approaches - Drilling Down Deeper Using Technology and Integrated Data Analyses

Dan A. Landau, MD

Blood (2019) 134 (Supplement_1): SCI-28.

https://doi.org/10.1182/blood-2019-121046

Published: 2019

Journal Articles

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Guldane Cengiz Seval, Atilla Uslu, MD, Ekin Kircali, Sinem Civriz Bozdag, MD, Klara Dalva, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Isinsu Kuzu, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Osman Ilhan, MD, Hamdi Akan, MD, Meral Beksac, MD, Gunhan Gurman, MD

Blood (2019) 134 (Supplement_1): 2019.

https://doi.org/10.1182/blood-2019-128750

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Wei Xu, MD PhD, Jie Jin, MD PhD, Keshu Zhou, MD, Li Wang, MD, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, MD, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 4000.

https://doi.org/10.1182/blood-2019-126707

Published: 2019

Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4001.

https://doi.org/10.1182/blood-2019-126951

Published: 2019

Journal Articles

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Michele Merli, MD, Benedetta Bianchi, MD, Lorenza Bertù, Andrea Ferrario, MD, Barbara Mora, Silvia Uccella, MD, Daniela Furlan, Maria Grazia Tibiletti, Simona Cattaneo, Fausto Sessa, Prof., Francesco Passamonti, Prof.

Blood (2019) 134 (Supplement_1): 4017.

https://doi.org/10.1182/blood-2019-130288

Published: 2019

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey

Blood (2019) 134 (Supplement_1): 2571.

https://doi.org/10.1182/blood-2019-128872

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Xavier Calvo, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3027.

https://doi.org/10.1182/blood-2019-122038

Published: 2019

Journal Articles

Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Xavier Calvo, MD PhD, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3029.

https://doi.org/10.1182/blood-2019-122061

Published: 2019

Journal Articles

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

William J Archibald, MDCPA, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Curtis A. Hanson, MD, Wei Ding, MD PhD, Amber Koehler, PA-C, MS, Eli Muchtar, MD, Suzanne R. Hayman, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Yucai Wang, MD PhD, Amie Fonder, PA-C, MS, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3037.

https://doi.org/10.1182/blood-2019-131154

Published: 2019

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Blood (2019) 134 (Supplement_1): 3039.

https://doi.org/10.1182/blood-2019-128706

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CLL cells are moved by the MARCKS brothers

CLL-IPI: valid in the era of oral inhibitors?

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Familial patterns of hematologic precursors

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Single Cell Approaches - Drilling Down Deeper Using Technology and Integrated Data Analyses

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only